# Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China

> **NCT03437837** · — · COMPLETED · sponsor: **Peking University First Hospital** · enrollment: 1077 (actual)

## Conditions studied

- Breast Cancer
- Neoadjuvant Therapy
- Neoplasm Staging
- Estrogen Receptor
- Histological Grade
- HER2
- Prognosis
- Predictive Value of Tests

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03437837
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-01
- **Primary completion:** 2018-09-29
- **Final completion:** 2018-09-29
- **Target enrollment:** 1077 (ACTUAL)
- **Last updated:** 2020-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03437837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03437837, "Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03437837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*